Biogen (NASDAQ:BIIB) Shares Unloaded Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on September 01st, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on August 18th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Home Depot (NYSE:HD) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Procter & Gamble (NYSE:PG) on 8/24/2026.
• Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 8/21/2026.
• Sold $15,001 – $50,000 in shares of Honeywell Aerospace (NASDAQ:HONA) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 8/18/2026.

Biogen Trading Up 0.8%

NASDAQ BIIB opened at $224.51 on Friday. The firm’s 50-day moving average is $209.44 and its two-hundred day moving average is $196.45. Biogen Inc. has a 12 month low of $135.39 and a 12 month high of $225.80. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The stock has a market capitalization of $33.17 billion, a P/E ratio of 39.74, a PEG ratio of 2.46 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the business earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 12.39 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System increased its holdings in Biogen by 21,439.6% during the 2nd quarter. California State Teachers Retirement System now owns 47,535,145 shares of the biotechnology company’s stock worth $10,270,443,000 after purchasing an additional 47,314,458 shares during the period. BlackRock Inc. purchased a new position in shares of Biogen in the 2nd quarter valued at about $3,453,878,000. Primecap Management Co. CA acquired a new position in shares of Biogen during the second quarter worth about $3,274,304,000. Geode Capital Management LLC grew its position in shares of Biogen by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after buying an additional 130,618 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Biogen by 5.3% during the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after buying an additional 155,828 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: China approved LEQEMBI’s subcutaneous autoinjector formulation for initiation treatment in early Alzheimer’s disease. The once-weekly, at-home option expands access beyond hospital-based infusions, could improve adherence, and may reduce clinic and healthcare-resource requirements. Launch is planned during Eisai’s fiscal 2026. Biogen co-commercializes LEQEMBI with Eisai, although Eisai leads development and has final decision-making authority. China approval of LEQEMBI subcutaneous formulation
• Positive Sentiment: U.S. patients can now receive LEQEMBI IQLIK at home through a weekly prefilled syringe or autoinjector, giving Biogen and Eisai a more convenient alternative to infusion-based therapy. This could lower treatment barriers and support broader commercial uptake of the Alzheimer’s franchise. Biogen brings at-home weekly Alzheimer’s injection to U.S. patients
• Positive Sentiment: Four-year data for zorevunersen, developed with Stoke Therapeutics, showed durable seizure reductions and continuing improvements in cognition and behavior for Dravet syndrome patients receiving the treatment alongside standard care. The reported completion of Phase 3 EMPEROR enrollment provides an additional late-stage development milestone and supports Biogen’s efforts to build growth beyond its established products. Long-term zorevunersen clinical data
• Neutral Sentiment: Investors remain focused on Biogen’s diversification strategy. The RayThera acquisition adds an early-stage immunology program, but its lead drug is only in Phase 1, making the deal a long-term opportunity rather than an immediate earnings contributor. Biogen’s immunology acquisition and balance sheet
• Negative Sentiment: Valuation and execution risks could limit further upside. BIIB is trading near its 52-week high, while earnings-based measures characterize the shares as expensive; zorevunersen remains investigational, and LEQEMBI’s subcutaneous formulation can cause injection-related reactions and still requires MRI monitoring for ARIA. Biogen valuation and Dravet data analysis

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BIIB shares. Royal Bank Of Canada increased their price objective on shares of Biogen from $240.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. HSBC reissued a “reduce” rating and issued a $157.00 target price on shares of Biogen in a research report on Monday, July 6th. Morgan Stanley raised their price target on Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. TD Cowen lifted their price objective on Biogen from $215.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Truist Financial raised Biogen from a “hold” rating to a “buy” rating and increased their target price for the stock from $190.00 to $235.00 in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $228.50.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.